# DESCRIPTION

## BACKGROUND OF THE INVENTION

- introduce genetic mechanisms
- limitations of chemical-based methodologies
- recent developments in degradation tags

## SUMMARY OF THE INVENTION

- define bifunctional compound structure
- introduce degradation tag system
- describe dTAG system components
- explain dTAG system operation
- outline methods of using dTAG system
- genetically modify cells
- contact cells with heterobifunctional compound
- determine changes in modified cells
- in vivo methods
- clinical methods
- advantages of present invention

## DETAILED DESCRIPTION OF THE INVENTION

- define technical and scientific terms
- specify meaning of singular forms
- define "about"
- define "comprising"
- define "consisting of"
- define "consisting essentially of"
- define "alkyl"
- provide examples of alkyl groups
- define "alkylene"
- provide examples of alkylene groups
- define "alkenyl"
- provide examples of alkenyl groups
- define "alkoxyl" and "alkoxy"
- define "alkoxylene"
- define "cyclic group"
- define "carbocyclic"
- provide examples of carbocyclyls
- define "heterocyclyl"
- provide examples of heterocyclyls
- specify heterocyclyl ring systems
- specify heterocyclyl monocycles
- specify heterocyclyl bicycles
- specify heterocyclyl spiro ring systems
- define "heterocyclic"
- define "N-heterocyclyl"
- define "C-heterocyclyl"
- define "heterocyclylalkyl" and "heterocyclylalkoxy"
- define aryl group
- define aralkyl group
- define aralkoxy group
- define heteroaryl group
- define heteroarylalkyl group
- define heteroaralkoxy group
- define N-heteroaryl group
- define C-heteroaryl group
- describe substituents
- describe binding of targeting ligand and targeted protein
- define FKBP12(F36V)-tagged protein
- describe binding of degron and E3 ubiquitin ligase
- introduce bifunctional compound formula I
- describe targeting ligand
- describe degron
- describe linker
- describe pharmaceutically acceptable salts
- describe isotopic derivatives
- describe stereoisomers
- describe chiral centers
- describe epimerization
- describe N-oxides
- describe crystalline forms
- describe active metabolites
- describe tautomers and solvated forms

### Targeting Ligands

- define targeting ligand structure

### Linkers

- describe linker structure
- provide examples of alkylene chain linkers
- describe interrupted alkylene chain linkers
- provide examples of polyethylene glycol chain linkers
- describe terminating groups of linkers
- provide examples of alkylene chains with functional groups
- describe heterocyclene and heteroarylene linkers
- provide examples of alkylene chains with heteroatoms
- describe polyethylene glycol chain linkers with functional groups
- provide examples of bifunctional compounds with linkers

### Degrons

- define degron structure

### Methods of Synthesis

- describe method for making bifunctional compounds
- provide synthetic schemes for bifunctional compounds
- describe dTAG system
- describe degradation of protein-dTAG hybrid
- describe genomic insertion of dTAG nucleic acid sequence
- describe modulation of protein-dTAG hybrid activity

### Proteins of Interest

- describe dTAG system for proteins of interest
- provide examples of genes involved in disorders
- describe genomic insertion of dTAG nucleic acid sequence
- describe modulation of protein-dTAG hybrid activity
- provide additional examples of proteins of interest

### Methods of Use

- conduct methods in vitro
- genetically modify cell with FKBP12(F36V)
- contact modified cells with bifunctional compound
- detect change in property of modified cell
- conduct methods in vivo
- genetically modify cell with FKBP12(F36V) in vivo
- introduce modified cells into rodent
- administer bifunctional compound to rodent
- detect change in property of rodent
- validate protein target associated with disease state
- use human cell, e.g., cancer cell line or non-cancerous cell line
- provide tunable control of CRISPR-Cas9 via degradation of Cas9-dTAG fused proteins
- insert dTAG in-frame with gene expressing endogenous protein of interest
- perform in-frame insertion of dTAG using CRISPR-Cas9 system
- produce knock-in endogenous protein-dTAG fusion proteins
- degrade fusion proteins in ligand-dependent, reversible, and dose-responsive fashion
- employ CRISPR-Cas9 system to insert expression cassette for dTAG
- use homologous recombination targeting vector
- introduce donor sequence into cell in circular or linear form
- protect ends of donor sequence from exonucleolytic degradation
- introduce donor polynucleotide into cell as part of vector molecule
- deliver donor polynucleotide by viruses or other means
- take advantage of well-characterized insertion strategies
- use CRISPR-Cas9 system to induce DSBs at target site
- use Cas9 variants, e.g., nickases, to nick single strand at target site
- use paired nickases to improve specificity
- form CRISPR complex at site of target sequence
- hybridize guide sequence to target sequence
- cleave one or both strands in or near target sequence
- form CRISPR complex with tracr sequence and Cas protein
- introduce vectors driving expression of CRISPR system elements into cell
- express CRISPR system elements from same or different regulatory elements
- use Cas proteins, e.g., Cas9, to induce nick or double-strand break into desired recognition site
- introduce guide sequence selection
- describe target sequence selection
- explain CRISPR-Cas system for inserting dTAG
- detail method of modifying expression of polynucleotide
- describe administration of CRISPR-Cas system and donor sequence
- list types of expression vectors
- describe delivery of nucleic acid sequences to cells
- reference prior art for delivering nucleic acid sequences
- describe viral-based systems for delivering nucleic acids
- detail retroviral vectors
- describe adenoviral vectors
- describe adeno-associated virus vectors
- describe lentiviral vectors
- describe non-integrating lentivirus vectors
- describe recombinant adeno-associated virus vectors
- describe replication-deficient recombinant adenoviral vectors
- describe packaging cells for forming virus particles
- describe modifying viral vectors for specificity to cell types
- describe delivering vectors in vivo
- describe delivering vectors ex vivo
- describe administering naked DNA
- describe synthesizing CRISPR-Cas system polypeptides in situ
- describe introducing CRISPR-Cas polynucleotide constructs into animal cells
- describe transient transformation methods
- describe viral and non-viral based gene transfer methods
- describe using ZFN, TALE, and TALEN systems
- describe non-viral vector delivery systems
- describe viral vector delivery systems
- reference prior art for gene therapy procedures
- describe preparing lipid:nucleic acid complexes
- describe targeted liposomes
- describe EnGenelC delivery vehicles
- describe bispecific antibodies for targeting tissues
- describe releasing contents of EDVs into cells

### Chimeric Antigen Receptor Protein (CAR)-dTAG Fusion Proteins

- introduce CAR-T cell therapy
- describe therapeutic efficacy in various cancers
- mention FDA-approved CAR-T cell therapies
- describe side effects of CAR-T cell therapy
- explain cytokine release syndrome
- explain tumor lysis syndrome
- motivate need for safety strategies
- introduce CAR-dTAG fusion proteins
- describe structure of CAR-dTAG fusion proteins
- specify location of dTAG in CAR
- describe tisagenlecleucel (Kymriah) immunotherapy
- describe axicabtagene ciloleucel (Yescarta) immunotherapy
- introduce nucleic acid encoding CAR
- describe preparation of nucleic acid
- introduce immune effector cells expressing CAR
- describe engineering of immune effector cells
- specify types of immune effector cells
- describe therapeutic agent for disease
- specify diseases treatable with CAR-expressing cells
- describe administration routes
- specify dosage amounts
- describe antigen binding moiety portion of CAR
- specify cancers treatable with CAR-expressing cells
- describe solid tumors treatable with CAR-expressing cells
- introduce immunologically effective amount
- describe dosage and treatment regime
- specify administration methods
- introduce subject in need of treatment
- describe modes of administration
- introduce therapeutically effective amount

### Dosage Amounts

- introduce therapeutically effective amount
- describe factors affecting dosage
- specify dosage range
- describe individual dosage formulation
- introduce frequency of administration
- describe administration cycles
- specify dosage amounts for different frequencies

### Pharmaceutical Kits

- introduce pharmaceutical kits
- describe contents of pharmaceutical kits

## EXAMPLES

- describe experimental conditions

### Example 1: Synthesis of (R)-3-(3,4-dimethoxyphenyl)-1-(2-(2-((7-(((S)-1-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-7-oxoheptyl)amino)-2-oxoethoxy)phenyl)propyl (S)-1-((S)-2-(3,4,5-trimethoxyphenyl)butanoyl)piperidine-2-carboxylate (1)

- prepare compound A
- prepare compound B
- prepare compound C
- prepare compound D
- couple compounds C and D
- purify compound 1
- characterize compound 1 by NMR
- characterize compound 1 by LC/MS

### Example 2: Synthesis of (R)-3-(3,4-dimethoxyphenyl)-1-(2-(2-((7-(((S)-1-((2R,4S)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-7-oxoheptyl)amino)-2-oxoethoxy)phenyl)propyl (S)-1-((S)-2-(3,4,5-trimethoxyphenyl)butanoyl)piperidine-2-carboxylate (2)

- prepare compound E
- prepare compound 2
- characterize compound 2 by NMR and LC/MS

### Example 3: Synthesis of (R)-3-(3,4-dimethoxyphenyl)-1-(2-(((S)-16-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidine-1-carbonyl)-17,17-dimethyl-2,14-dioxo-6,9,12-trioxa-3,15-diazaoctadecyl)oxy)phenyl)propyl (S)-1-((S)-2-(3,4,5-trimethoxyphenyl)butanoyl)piperidine-2-carboxylate (3)

- prepare compound 3

### Example 4: Synthesis of (R)-3-(3,4-dimethoxyphenyl)-1-(2-(O)-16-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidine-1-carbonyl)-17,17-dimethyl-2,14-dioxo-6,9,12-trioxa-3,15-diazaoctadecyl)oxy)phenyl)propyl (9-14(9-2-(3,4,5-trimethoxyphenyl)butanoyl)piperidine-2-carboxylate (4)

- prepare compound 4

### Example 5: Anti-Proliferation in NIH/3T3 Cells Expressing FKBP12F36V-KRASG12V by ATPlite™ Assay

- measure anti-proliferative effects

### Example 6: Immunoblotting of PATU-8902 LACZ-FKBP12F36V Clone

- monitor LACZ-FKBP12F36V degradation

### Example 7: Immunoblotting of PATU-8902 LACZ-FKBP12F36V Clone

- monitor LACZ-FKBP12F36V and CDK9 degradation

### Example 8: Immunoblotting of PATU-8902 FKBP12F36V-KRASG12V; KRAS−/− Clone

- treat cells with dTAG molecules
- analyze protein levels via immunoblotting

### Example 9: Immunoblotting of PATU-8902 FKBP12F36V-KRASG12V KRAS−/− Clone

- treat cells with DMSO, Carflizomib, or MLN4924
- treat cells with compound 1
- analyze protein levels via immunoblotting
- monitor FKBP12F36V-KRASG12V degradation
- evaluate changes in ERK signaling
- evaluate changes in AKT signaling
- use α-TUBULIN as a loading control
- show potent degradation of FKBP12F36V-KRASG12V
- show diminished levels of pERK and pAKT
- show no effect of compound 2 and compound 5
- indicate mutant KRAS degradation by co-opting CRBN and VHL E3 ligases
- indicate rapid loss of downstream signaling pathways
- summarize results

